Browse studies, page 1080

Page 1080 of 1,203, newest first. Search them all at once, ranked by relevance, in Evidence Hub.

• A Meta-Analysis of the Effect of Sodium Glucose Cotransporter-2 Inhibitors on Metabolic Parameters in Patients With Polycystic Ovary Syndrome Frontiers in endocrinology, 2022
• Effects of SGLT2 inhibitors on haematocrit and haemoglobin levels and the associated cardiorenal benefits in T2DM patients: A meta-analysis Journal of cellular and molecular medicine, 2022
• Effect of sodium-glucose cotransporter-2 inhibitors on aldosterone and renin levels in diabetes mellitus type 2 patients: a systematic review and meta-analysis Scientific reports, 2022
• Anti-diabetic agents and the risks of dementia in patients with type 2 diabetes: a systematic review and network meta-analysis of observational studies and randomized controlled trials Alzheimer's research & therapy, 2024
• Sodium-glucose co-transporter 2 inhibitors in heart failure with mildly reduced or preserved ejection fraction: an updated systematic review and meta-analysis European journal of medical research, 2022
• Association between the beta-blockers, calcium channel blockers, all-cause mortality and length of hospitalization in patients with heart failure with preserved ejection fraction: A meta-analysis of randomized controlled trials Clinical cardiology, 2023
• Effects of first-line antidiabetic drugs on the improvement of arterial stiffness: A Bayesian network meta-analysis Journal of diabetes, 2023
• Relative frequency of urinary tract infections in patients affected by diabetes mellitus type 2 treated with metformin and SGLT2 inhibitor. Network meta-analysis Orvosi hetilap, 2020
• The effect of semaglutide on blood pressure in patients with type-2 diabetes: a systematic review and meta-analysis Endocrine, 2024
• Network meta-analysis on the effects of finerenone versus SGLT2 inhibitors and GLP-1 receptor agonists on cardiovascular and renal outcomes in patients with type 2 diabetes mellitus and chronic kidney disease Cardiovascular diabetology, 2022
• Effects of SGLT-2 Inhibitors on Vascular Endothelial Function and Arterial Stiffness in Subjects With Type 2 Diabetes: A Systematic Review and Meta-Analysis of Randomized Controlled Trials Frontiers in endocrinology, 2022
• Racial, ethnic and regional differences in the effect of sodium-glucose co-transporter 2 inhibitors and glucagon-like peptide 1 receptor agonists on cardiovascular and renal outcomes: a systematic review and meta-analysis of cardiovascular outcome trials Journal of the Royal Society of Medicine, 2024
• SGLT-2 inhibitors improve cardiovascular and renal outcomes in patients with CKD: a systematic review and meta-analysis Scientific reports, 2023
• The cardiovascular effects of SGLT2 inhibitors, RAS inhibitors, and ARN inhibitors in heart failure ESC heart failure, 2023
• Impact of anemia on clinical outcomes in patients with acute heart failure: A systematic review and meta-analysis Clinical cardiology, 2024
• Sodium-glucose co-transporter protein 2 (SGLT2) inhibitors for people with chronic kidney disease and diabetes The Cochrane database of systematic reviews, 2024
• Abrupt Decline in Estimated Glomerular Filtration Rate after Initiating Sodium-Glucose Cotransporter 2 Inhibitors Predicts Clinical Outcomes: A Systematic Review and Meta-Analysis Diabetes & metabolism journal, 2024
• First-line treatment with sodium-glucose cotransporter 2 inhibitors and glucagon-like peptide-1 receptor agonists in type 2 diabetic population at low risk of cardiovascular disease: a meta-analysis Frontiers in endocrinology, 2024
• Comparative efficacy and safety of SGLT2is and ns-MRAs in patients with diabetic kidney disease: a systematic review and network meta-analysis Frontiers in endocrinology, 2024
• SGLT-2 inhibitors and prevention of contrast-induced nephropathy in patients with diabetes undergoing coronary angiography and percutaneous coronary interventions: systematic review and meta-analysis Frontiers in endocrinology, 2023
• Cardiovascular outcomes and safety of SGLT2 inhibitors in chronic kidney disease patients Frontiers in endocrinology, 2023
• Sodium-glucose cotransporter 2 inhibitors and outcomes in transthyretin amyloid cardiomyopathy: Systematic review and meta-analysis European journal of clinical investigation, 2025
• SGLT2 inhibitors among patients with heart failure with preserved ejection fraction: A meta-analysis of randomised controlled trials Medicine, 2023
• Efficacy and Safety of SGLT2 Inhibitors in Pediatric Patients and Young Adults: A Systematic Review and Meta-Analysis of Randomized Controlled Trials Pediatric diabetes, 2024
• Cardiovascular and renal outcomes of combined SGLT2 inhibitors and GLP-1 receptor agonists versus monotherapy in patients with type 2 diabetes mellitus: a network meta-analysis CMAJ : Canadian Medical Association journal = journal de l'Association medicale canadienne, 2026
• Efficacy of SGLT2 inhibitors, GLP-1 receptor agonists, and aerobic exercise for moderate-to-severe obstructive sleep apnea in overweight or obese patients: a network meta-analysis Frontiers in endocrinology, 2026
• Effect of GLP-1 Receptor Agonists on Post-Ablation Atrial Fibrillation Recurrence: A Meta‑Analysis Pacing and clinical electrophysiology : PACE, 2026
• High-dose sodium-glucose co-transporter-2 inhibitors are superior in type 2 diabetes: A meta-analysis of randomized clinical trials Diabetes, obesity & metabolism, 2021
• Conducting and interpreting results of network meta-analyses in type 2 diabetes mellitus: A review of network meta-analyses that include sodium glucose co-transporter 2 inhibitors Diabetes research and clinical practice, 2019
• Genito-urinary infectious adverse events related to sodium glucose cotransporter-2 inhibitors: a network meta-analysis and meta-regression Expert review of clinical pharmacology, 2024
• Peripheral artery disease and amputations with Sodium-Glucose co-Transporter-2 (SGLT-2) inhibitors: A meta-analysis of randomized controlled trials Diabetes research and clinical practice, 2019
• Effects of reducing blood pressure on cardiovascular outcomes and mortality in patients with type 2 diabetes: Focus on SGLT2 inhibitors and EMPA-REG OUTCOME. Diabetes research and clinical practice, 2016
• Effects of sodium-glucose cotransporter 1 and 2 inhibitors on cardiovascular and kidney outcomes in type 2 diabetes: A meta-analysis update American heart journal, 2021
• Sodium-glucose cotransporter 2 (SGLT2) inhibitors and fracture risk in patients with type 2 diabetes mellitus: A meta-analysis Diabetes/metabolism research and reviews, 2017
• Sodium-glucose co-transporter-2 inhibitors for the prevention of cardiorenal outcomes in type 2 diabetes: An updated meta-analysis Diabetes, obesity & metabolism, 2021
• Comparison of GLP-1 Receptor Agonists, SGLT-2 Inhibitors, and DPP-4 Inhibitors as an Add-On Drug to Insulin Combined With Oral Hypoglycemic Drugs: Umbrella Review Journal of diabetes research, 2024
• Ketone Bodies after Cardiac Arrest: A Narrative Review and the Rationale for Use Cells, 2024
• SGLT2 inhibitors attenuate endothelial to mesenchymal transition and cardiac fibroblast activation Scientific reports, 2024
• Translating Basic Science to Clinical Applications: A Narrative Review of Repurposed Pharmacological Agents in Preclinical Models of Diabetic Neuropathy Biomedicines, 2025
• Risk of bone fracture by using dipeptidyl peptidase-4 inhibitors, glucagon-like peptide-1 receptor agonists, or sodium-glucose cotransporter-2 inhibitors in patients with type 2 diabetes mellitus: a network meta-analysis of population-based cohort studies Frontiers in endocrinology, 2024
• Safety and effectiveness of empagliflozin according to body mass index in Japanese patients with type 2 diabetes: a subgroup analysis of a 3-year post-marketing surveillance study Expert opinion on drug safety, 2022
• The Role of ARNI in Enhancing Outcomes of Cardiac Resynchronization Therapy: A Comprehensive Review Journal of clinical medicine, 2025
• Sexual Dimorphism and Menopausal Transition: A Narrative Review of the Metabolic and Physical Effects of Intermittent Fasting Nutrients, 2026
• Mechanism of substrate recognition and release of human SGLT2 Nature communications, 2025
• Heart Failure and All-Cause Hospitalizations in Patients With Heart Failure: A Meta-Analysis JAMA network open, 2024
• SGLT ‐2 inhibitors enhance the effect of metformin to ameliorate hormonal changes and inflammatory markers in a rat PCOS model Physiological reports, 2023
• An Integrated Text Mining Approach for Discovering Pharmacological Effects, Drug Combinations, and Repurposing Opportunities of ACE Inhibitors International journal of molecular sciences, 2026
• Plant-derived Natural Products in Neurological and Psychiatric Disorders: Mechanisms of Action and Synergistic Roles with Probiotics Molecular neurobiology, 2026
• Heart Failure in the Molecular Era: Redefining Our Understanding of Disease Mechanisms and Perspectives Biomedicines, 2026
• Safety of Drugs in Breastfeeding Women With CKD Kidney international reports, 2025
• Mechanistic Role of Disulfidptosis in Type 2 Diabetes Mellitus Molecular nutrition & food research, 2026
• The effects of non-insulin anti-diabetic medications on the diabetic microvascular complications: a systematic review and meta-analysis of randomized clinical trials BMC endocrine disorders, 2025
• Impact of SGLT2 inhibition on markers of reverse cardiac remodelling in heart failure: Systematic review and meta-analysis ESC heart failure, 2024
• Exploring the comparative cardiovascular death benefits of sodium-glucose cotransporter 2 inhibitors in type 2 diabetes: a frequentist and Bayesian network meta-analysis-based scoring Frontiers in endocrinology, 2023
• The TREM2 paradox in fibrosis: a unified mechanism for opposite outcomes across organs Frontiers in immunology, 2026
• The Use of Empagliflozin Post Myocardial Infarction Cureus, 2023
• Pathophysiological basis of the cardiological benefits of SGLT-2 inhibitors: a narrative review Cardiovascular diabetology, 2023
• Mechanism-guided pharmacotherapy for cardiometabolic multimorbidity: from pathophysiology to phenotype-prioritized treatment Frontiers in endocrinology, 2025
• Divergent Renal Benefits of Sodium-Glucose Cotransporter-2 Inhibitors and Mineralocorticoid Receptor Antagonists in Nondiabetic Kidney Disease Kidney & blood pressure research, 2026
• SGLT2 inhibitors versus GLP-1 receptor agonists for major adverse cardiovascular events in type 2 diabetes: a systematic review and meta-analysis of randomized controlled trials BMC cardiovascular disorders, 2025
• PersADE: a database of personalized adverse drug events and their underlying molecular mechanisms Nucleic acids research, 2026
• SGLT2 inhibitor dapagliflozin treats heart failure with preserved ejection fraction via the SIRT1/PGC-1α pathway Acta biochimica et biophysica Sinica, 2026
• Targeting the gut microbiome for type 2 diabetes management: a scoping review of systematic reviews and meta-analyses Frontiers in endocrinology, 2026
• Comparative Efficacy and Safety of Cardio-Renoprotective Pharmacological Interventions in Chronic Kidney Disease: An Umbrella Review of Network Meta-Analyses and a Multicriteria Decision Analysis Biomolecules, 2024
• Integrative gene-metabolite network analysis of GLP-1 receptor agonists and related incretin pathways in cardiometabolic health NPJ systems biology and applications, 2025
• Metabolic Crosstalk in Diabetic Kidney Disease: Synergistic Effects of Glucotoxicity and Lipotoxicity Diabetes, metabolic syndrome and obesity : targets and therapy, 2026
• Adverse drug events in cost-effectiveness models of pharmacological interventions for diabetes, diabetic retinopathy, and diabetic macular edema: a scoping review JBI evidence synthesis, 2024
• A Systematic Review of Gut Microbiota Diversity: A Key Player in the Management and Prevention of Diabetes Mellitus Cureus, 2024
• Sodium-Glucose Transporter-2 Inhibitors (SGLT2i) and Myocardial Ischemia: Another Compelling Reason to Consider These Agents Regardless of Diabetes International journal of molecular sciences, 2025
• Comparative efficacy of multiple drugs for non-alcoholic fatty liver disease: a Bayesian network meta-analysis European journal of medical research, 2025
• Newer glucose-lowering drugs reduce the risk of late-onset seizure and epilepsy: A meta-analysis Epilepsia open, 2024
• Euglycemic Diabetic Ketoacidosis and Its Prevention in Elective Surgical Patients Taking Sodium-Glucose Linked Transporter 2 Inhibitors: An International Perspective Arthroplasty today, 2025
• Docking-Based Classification of SGLT2 Inhibitors Molecules (Basel, Switzerland), 2025
• SGLT2 Inhibitors to Slow Chronic Kidney Disease Progression: A Review Clinical therapeutics, 2024
• Evaluating the potential of metabolic drugs in obstructive sleep apnea and obesity: a narrative review Journal of clinical sleep medicine : JCSM : official publication of the American Academy of Sleep Medicine, 2025
• Repurposing FDA-approved drugs and natural compounds to inhibit the RNA-dependent RNA polymerase domain of dengue virus 2 or dengue virus 3 Scientific reports, 2025
• Cardiac remodelling in type 2 diabetes: Pathophysiological mechanisms and opportunities for multiscale computational modelling and simulation The Journal of physiology, 2026
• Beyond safety: adverse events and unanticipated advantages of SGLT2 inhibitors European journal of clinical pharmacology, 2026
• Kidney-heart crosstalk: the extracellular vesicles connection Nephrology, dialysis, transplantation : official publication of the European Dialysis and Transplant Association - European Renal Association, 2026
• Update on the Efficacy and Safety of Sodium-Glucose Co-Transporter 2 Inhibitors in Patients with Chronic Diseases: A Systematic Review and Meta-Analysis Medicina (Kaunas, Lithuania), 2025
• Impact of Opuntia ficus-indica Juice and Empagliflozin on Glycemic Control in Rats Current issues in molecular biology, 2024
• Orphan GPCRs in diabetes mellitus: metabolic control, inflammation, and drug development Frontiers in endocrinology, 2026
• Bibliometric analysis of SGLT2 inhibitor treatment for diabetic kidney disease Renal failure, 2026
• Multi-dimensional roles of sodium-glucose cotransporter 2 inhibitors: beyond hypoglycemic and cardiorenal protection Frontiers in endocrinology, 2025
• Effects of Sodium-Glucose Cotransporter 2 Inhibitors on Body Weight, BMI, and Body Composition in Adults With Type 2 Diabetes Mellitus: A Systematic Review Cureus, 2024
• Stacked ensemble learning and in-silico profiling reveal dual DPP-IV and SGLT2 inhibitors from Moringa oleifera metabolites Scientific reports, 2026
• Treatment of left ventricular dysfunction during cancer therapy: a comprehensive review Drugs in context, 2026
• Pre-PCI SGLT2 inhibitors and contrast-induced nephropathy in acute myocardial infarction: A meta-analysis Medicine, 2025
• Sodium-glucose cotransporter 2 inhibitors for diabetic neuropathy: a protocol for a systematic review and meta-analysis BMJ open, 2026
• Empagliflozin as Add-on Therapy in Patients With Type 2 Diabetes Inadequately Controlled With Linagliptin and Metformin: A 24-Week Randomized, Double-Blind, Parallel-Group Trial Diabetes Care, 2016
• Anti-inflammatory effects of empagliflozin in patients with type 2 diabetes and insulin resistance Diabetology & Metabolic Syndrome, 2018
• Effect of empagliflozin on ketone bodies in patients with stable chronic heart failure Cardiovascular Diabetology, 2021
• Efficacy of empagliflozin on heart failure and renal outcomes in patients with atrial fibrillation: data from the EMPA-REG OUTCOME trial European Journal of Heart Failure, 2019
• Empagliflozin on top of metformin treatment improves arterial function in patients with type 1 diabetes mellitus Cardiovascular Diabetology, 2018
• Empagliflozin and Cardiovascular Outcomes in Asian Patients With Type 2 Diabetes and Established Cardiovascular Disease ― Results From EMPA-REG OUTCOME® ― Circulation Journal, 2016
• The effect of empagliflozin on muscle sympathetic nerve activity in patients with type II diabetes mellitus Journal of the American Society of Hypertension, 2017
• Semaglutide and Cardiovascular Outcomes in Patients with Type 2 Diabetes New England Journal of Medicine, 2016
• Dapagliflozin in Patients with Chronic Kidney Disease New England Journal of Medicine, 2020
• Empagliflozin as Add-on Therapy to Pioglitazone With or Without Metformin in Patients With Type 2 Diabetes Mellitus Clinical Therapeutics, 2015
• Evaluation of the Effects of Sodium–Glucose Co-Transporter 2 Inhibition with Empagliflozin on Morbidity and Mortality in Patients with Chronic Heart Failure and a Preserved Ejection Fraction: Rationale for and Design of the EMPEROR-Preserved Trial European Journal of Heart Failure, 2019